Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy

Journal of Infectious Diseases

Volumn 184, Issue 6, 2001, Pages 794-798

  Urban, Carl ^a   Rahman, Naim ^a   Zhao, Xilin ^b   Mariano, Noriel ^a   Segal Maurer, Sorana ^a   Drlica, Karl ^b   Rahal, James J ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATION; BACTERIUM MUTANT; CASE REPORT; DRUG BLOOD LEVEL; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NUCLEOTIDE SEQUENCE; PNEUMONIA; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STREPTOCOCCUS PNEUMONIAE;

AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTI-INFECTIVE AGENTS; DNA GYRASE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MICROBIAL; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OFLOXACIN; PNEUMONIA, PNEUMOCOCCAL; POINT MUTATION; STREPTOCOCCUS PNEUMONIAE;

EID: 0035884479     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/323086     Document Type: Article

References (15)

1. Surveillance of antimicrobial resistance among respiratory tract pathogens in the United States, 1997-1998
2. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
3. The future of fluoroquinolones
4. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium boris BCG and Staphylococcus aureus
5. Mutant prevention concentrations (MPC) for fluoroquinolones with clinical isolates of Streptococcus pneumoniae
6. Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones
7. Clinical pharmacology of the fluoroquinolones: Studies in human dynamic/kinetic models
8. Pharmacodynamics to combat resistance
9. Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers
10. Pharmacokinetics of grepafloxacin
11. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone
12. Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms
13. Pharmacokinetics, safety, and tolerability of ascending single dose of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects
14. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis
15. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy